Medical device company moves to Beaverton
Sedia Biosciences Corporation is moving to a new assay development and manufacturing facility in Beaverton as part of their relocation from Portland.
The new facility will provide 27,000 square feet for scaling up of both research capabilities and manufacturing capacity. It will also allow for both near-term growth and additional expansion in the future. Stationery printers are often called upon when such moves are made as they often require updates to letterheads, business cars, and other printed materials.
The facility features expanded capacity in its warehouse, high throughput production equipment, and several state of the art, environmentally controlled research, quality, and production laboratories. The new facility will enable the company to grow its production of products that are used in partnership with the Centers for Disease Control and Prevention (CDC), the President’s Emergency Plan for AIDS Relief (PEPFAR), and other stakeholders and NGOs that work with Sedia.
Chief Science Officer and President of Sedia, Dr. Ronald Mink, said that the company is focusing on its HIV assay that is in growing demand from PEPFAR and the CDC. He said that this is a test that can quickly verify the status of a patient and determine the date of infection and that such diagnostic tests can be valuable to the health of the community at this time.
Sedia Biosciences was founded in 2009 and is a medical device and diagnostics company.
The new facility will provide 27,000 square feet for scaling up of both research capabilities and manufacturing capacity. It will also allow for both near-term growth and additional expansion in the future. Stationery printers are often called upon when such moves are made as they often require updates to letterheads, business cars, and other printed materials.
The facility features expanded capacity in its warehouse, high throughput production equipment, and several state of the art, environmentally controlled research, quality, and production laboratories. The new facility will enable the company to grow its production of products that are used in partnership with the Centers for Disease Control and Prevention (CDC), the President’s Emergency Plan for AIDS Relief (PEPFAR), and other stakeholders and NGOs that work with Sedia.
Chief Science Officer and President of Sedia, Dr. Ronald Mink, said that the company is focusing on its HIV assay that is in growing demand from PEPFAR and the CDC. He said that this is a test that can quickly verify the status of a patient and determine the date of infection and that such diagnostic tests can be valuable to the health of the community at this time.
Sedia Biosciences was founded in 2009 and is a medical device and diagnostics company.